Antibiotic therapy for musculoskeletal infections

Journal of Bone and Joint Surgery

Volumn 83, Issue 12, 2001, Pages 1878-1890

  Mader, J T ^a   Wang, J ^a   Calhoun, J H ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAMASE INHIBITOR; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; CLOXACILLIN; DALFOPRISTIN PLUS QUINUPRISTIN; DICLOXACILLIN; FLUCLOXACILLIN; IMIPENEM; MACROLIDE; METICILLIN; MEZLOCILLIN; NAFCILLIN; NEUROMUSCULAR BLOCKING AGENT; OXACILLIN; OXAZOLIDINE DERIVATIVE; PENICILLIN DERIVATIVE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULTAMICILLIN; TETRACYCLINE DERIVATIVE; TICARCILLIN; TIMENTIN; UNINDEXED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BONE INFECTION; CONFERENCE PAPER; DRUG CHOICE; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG POTENTIATION; FOOD DRUG INTERACTION; HUMAN; MUSCULOSKELETAL DISEASE; MYOSITIS; PRIORITY JOURNAL; TOXICITY;

EID: 0035211988     PISSN: 00219355     EISSN: None     Source Type: Journal    
DOI: 10.2106/00004623-200112000-00017     Document Type: Conference Paper

References (128)

1. Anaphylaxis in the United States: An investigation into its epidemiology
2. Immunologic mechanisms of penicillin allergy. A haptenic model system for the study of allergic diseases in man
3. Allergic reactions to drugs and biologic agents
4. A ten-year assessment of methicillin-associated side effects
5. Antibiotics in the treatment of chronic staphylococcal osteomyelitis
6. Hepatitis from intravenous high-dose oxacillin therapy: Findings in an adult inpatient population
7. Aminopenicillins - Clinical pharmacology and use in disease states
8. Carbenicillin and ticarcillin
9. Comparative in vitro activity and clinical pharmacology of ticarcillin and carbenicillin
10. Piperacillin, a new penicillin active against many bacteria resistant to other penicillins
11. The in-vitro activity of mezlocillin against community hospital isolates in comparison to other penicillins and cephalosporins
12. In vivo inactivation of gentamicin by carbenicillin and ticarcillin
13. In vivo inactivation of tobramycin by ticarcillin. A case report
14. Effect of concomitant administration of piperacillin on the dispositions of isepamicin and gentamicin in patients with end-stage renal disease
15. Effect of ticarcillin on gentamicin and tobramycin pharmacokinetics in a patient with end-stage renal disease
16. Drug inhibition of penicillin tubular secretion: Concordance between in vitro and clinical findings
17. Clavulanic acid, a novel inhibitor of beta-lactamases
18. The inhibition of staphylococcal beta-lactamase by clavulanic acid
19. The beta-lactamase of gram-negative bacteria and their possible physiological role
20. Relative inactivation by Staphylococcus aureus of eight cephalosporin antibiotics
21. Pharmacokinetics of cefazolin compared with other cephalosporins
22. Future prospects and past problems in antimicrobial therapy: The role of cefoxitin
23. Review of in vitro activity of third-generation cephalosporins and other newer beta-lactam antibiotics against clinically important bacteria
24. Antibacterial activity and beta-lactamase stability of ceftazidime, an aminothiazolyl cephalosporin potentially active against Pseudomonas aeruginosa
25. Clinical efficacy of ceftazidime. Treatment of serious infection due to multiresistant Pseudomonas and other gram-negative bacteria
26. Disulfiram-like reaction to beta-lactams
27. On the disulfiram-like activity of moxalactam
28. Disulfiram-like reaction to moxalactam after celiac plexus alcohol block
29. Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia
30. Ethanol-cephalosporin antibiotic interactions: An animal model for the detection of disulfiram (Antabuse)-like effects
31. Cefoperazone-induced coagulopathy
32. Hypoprothombinemia and cefotaxime
33. Hypoprothrombinaemia associated with use of cephamandole
34. Hypoprothrombinemia associated with cefoperazone treatment
35. Cefotetan and hypoprothrombinemia
36. Azthreonam (SQ 26,766), a synthetic monobactam specifically active against aerobic gram-negative bacteria
37. Adverse effects of monobactams and carbapenems
38. Carbapenems and monobactams: Imipenem, meropenem, and aztreonam
39. Comparative in vitro evaluation of N-formimidoyl thienamycin against gram-positive and gram-negative aerobic and anaerobic species and its beta-lactamase stability
40. Potentiation of neurotoxic side effects by coadministration of imipenem to cyclosporine therapy in a kidney transplant recipient-synergism of side effects or drug interaction?
41. Increased risk of central nervous system toxicity in patients treated with ciclosporin and imipenem/cilastatin
42. Vancomycin
43. Vancomycin therapy for methicillinresistant Staphylococcus aureus
44. Antimicrobial susceptibility and selection or resistance among Staphylococcus epidermidis isolates recovered from patients with infections of indwelling foreign devices
45. The life and times of the Enterococcus
46. Enterococcal resistance to vancomycin and related cyclic glycopeptide antibiotics
47. Red man syndrome
48. Red man syndrome: Incidence, etiology, and prophylaxis
49. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981
50. Nephrotoxicity associated with vancomycin-aminoglycoside therapy in four children
51. Risk of nephrotoxicity with combination vancomycin-aminoglycoside antibiotic therapy
52. The effect of tobramycin on the renal handling of vancomycin
53. Vancomycin-induced neutropenia associated with fever: Similarities between two immune-mediated drug reactions
54. Vancomycin induced neutropenia
55. Vancomycin-induced thrombocytopenia: A challenge and rechallenge
56. Vancomycin-associated thrombocytopenia: Case report and review of the literature
57. In vitro susceptibility of anaerobes: Comparison of clindamycin and other antimicrobial agents
58. Clindamycin treatment of experimental chronic osteomyelitis due to Staphylococcus aureus
59. Comparative penetration of metronidazole, clindamycin, chloramphenicol, cefoxitin, ticarcillin, and moxalactam into bone
60. The spectrum of colitis associated with lincomycin and clindamycin therapy
61. Clindamycin enhances a nondepolarizing neuromuscular blockade
62. Clindamycin-induced neuromuscular blockade
63. Neuromuscular blockade after clindamycin administration: A case report
64. Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: An update focused on clarithromycin, azithromycin and dirithromycin
65. Treatment of vancomycin-resistant enterococci, with a focus on quinupristin-dalfopristin
66. Safety and tolerability of quinupristin/dalfopristin: Administration guidelines
67. Quinupristin/dalfopristin (RP 59500): A new streptogramin antibiotic
68. Arthralgias and myalgias related to quinupristin-dalfopristin administration
69. Decrease of tetracycline absorption in man by sodium bicarbonate
70. Effect of cimetidine and antacids on gastrointestinal absorption of tetracycline
71. Effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline
72. Oxazolidinones: New antibacterial agents
73. Oxazolidinones: A review
74. The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials
75. Experimental osteomyelitis. V. Therapeutic trials with oxacillin and sisomicin alone and in combination
76. Selection and characterization of strains of Staphylococcus aureus displaying unusual resistance to aminoglycosides
77. In vitro studies with Sch 21420 and Sch 22591: Activity in comparison with six other aminoglycosides and synergy with penicillin against enterococci
78. Susceptibility of Staphylococcus aureus and Staphylococcus epidermidis to 65 antibiotics
79. Staphylococcus aureus endocarditis. Combined therapy with vancomycin and rifampin
80. Drug interactions with antibacterial agents
81. Interaction of rifampicin with other drugs
82. Update on rifampin drug interactions, III
83. Interactions of antitubercular drugs
84. Pharmacokinetic study of the interaction between rifampicin and ketoconazole
85. Quinolones and osteomyelitis: State-of-the-art
86. Levofloxacin and trovafloxacin: The next generation of fluoroquinolones?
87. Comparative in vitro activities of trovafloxacin (CP 99,219) and other antimicrobials against clinically significant anaerobes
88. Increasing resistance of enterococci to ciprofloxacin
89. Rapid development of ciprofloxacin resistance in methicillin-susceptible and resistant Staphylococcus aureus
90. Chondrotoxicity of ciprofloxacin in immature beagle dogs; immunohistochemistry, electron microscopy and drug plasma concentrates
91. Adverse reactions to fluoroquinolones. An overview on mechanistic aspects
92. Drug-drug interactions with ciprofloxacin and other fluoroquinolones
93. Synergy of trimethoprimsulfonamethoxazole
94. Trimethoprimsulfamethoxazole in the United States
95. Observations relating to an inter-hospital outbreak of methicillin-resistant Staphylococcus aureus: Role of antimicrobial therapy in infection control
96. Letter: Interaction of sulfisoxazole and warfarin
97. Potentiation of warfarin anticoagulation by sulfisoxazole
98. The effect of different sulfonamides on phenytoin metabolism in man
99. Potentiation of acetohexamide hypoglycemia by phenylbutazone
100. Mechanisms of inhibition of tolbutamide metabolism: Phenylbutazone, oxyphenbutazone, sulfaphenazole
101. Sulfonamidesulfonylurea interaction
102. Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction
103. Antibiotics alter methotrexate metabolism and excretion
104. Metronidazole
105. Antibiotic sensitivity testing. Report of an international collaborative study
106. A method of determining the effective therapeutic level in the treatment of subacute bacterial endocarditis with penicillin. A preliminary report
107. Variation in performance of the serum bactericidal test
108. Serum dilution test for bactericidal activity. I. Selection of a physiologic diluent
109. Serum dilution test for bactericidal activity. II. Standardization and correlation with antimicrobial assays and susceptibility tests
110. Laboratory tests used to guide antimicrobial therapy
111. Oral antibiotic therapy for skeletal infections in children. II. Therapy of osteomyelitis and suppurative arthritis
112. Drug use in first pregnancy and lactation: A population-based survey among Danish women
113. Treatment of skin and soft-tissue infections
114. The host and the skeletal infection: Classification and pathogenesis of acute bacterial bone and joint sepsis
115. Septic arthritis
116. Experimental osteomyelitis. 3. Treatment with cephaloridine
117. Randomized evaluation of ceftazidime or ticarcillin and tobramycin for the treatment of osteomyelitis caused by gram-negative bacilli
118. Chronic osteomyelitis caused by Staphylococcus aureus: Controlled clinical trial of nafcillin therapy and nafcillin-rifampin therapy
119. Oral ciprofloxacin compared with standard parenteral antibiotic therapy for chronic osteomyelitis in adults
120. Oral ciprofloxacin compared with parenteral antibiotics in the treatment of osteomyelitis
121. Ofloxacin versus parenteral therapy for chronic osteomyelitis
122. Randomized trial of ciprofloxacin compared with other antimicrobial therapy in the treatment of osteomyelitis
123. Cefotaxime in the treatment of chronic osteomyelitis caused by gramnegative bacilli
124. A comparison of short- and long-term intravenous antibiotic therapy in the postoperative management of adult osteomyelitis
125. Four week intravenous antibiotic therapy versus two week intravenous antibiotic therapy versus two week intravenous plus four week oral antibiotic therapy in the treatment of long bone osteomyelitis
126. Osteomyelitis